Respiratory syncytial virus is the second most common cause of infant mortality and a major
cause of morbidity and mortality in older adults (aged> 60 years). Efforts to develop a …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

Background Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality
among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized …

Despite advances in molecular biology, genetics, computation, and medicinal chemistry,
infectious disease remains an ominous threat to public health. Addressing the challenges …

The new SARS-CoV-2 virus is an RNA virus that belongs to the Coronaviridae family and
causes COVID-19 disease. The newly sequenced virus appears to originate in China and …

Immunization is a cornerstone of public health policy and is demonstrably highly cost-
effective when used to protect child health. Although it could be argued that immunology has …

The development of effective vaccines to combat infectious diseases is a complex multi-year
and multi-stakeholder process. To accelerate the development of vaccines for coronavirus …

The use of antibiotics has enabled the successful treatment of bacterial infections, saving the
lives and improving the health of many patients worldwide. However, the emergence and …

The large global burden of respiratory syncytial virus (RSV) respiratory tract infections in
young children and older adults has gained increased recognition in recent years. Recent …

A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to
control the coronavirus disease 2019 (COVID-19) global pandemic. Structural studies have …